Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS Without Diarrhea (Including IBS-Constipation) | US | 2019

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes, constipation predominant, diarrhea predominant, and mixed; however, prior to 2017, only two ICD-10 codes existed: IBS with diarrhea and IBS without diarrhea. For the purposes of this analysis, we focus on the IBS without diarrhea population, which includes IBS-constipation (IBS-C). Limited treatment options are available for IBS, and only a few drugs have secured an FDA approval for IBS-C. Current treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan’s Linzess and Synergy Pharmaceuticals’ Trulance), and bicyclic fatty acids (Takeda’s Amitiza), all of which are only moderately effective in treating the disease.


  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed IBS without diarrhea (including IBS-C)patients? What are the quarterly trends in prescribing among recently treated and new diagnosed IBS without diarrhea (including IBS-C) patients?
  • How have Linzess and Trulance been integrated into the treatment algorithm?
  • What proportion of IBS without diarrhea (including IBS-C) patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of IBS without diarrhea (including IBS-C) patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with IBS without diarrhea (including IBS-C)?


Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing brand share.

Login to access report